CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 3556135
• 负责人: ROBERT W CAREY
• 金额: $ 14.58万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-04-01 至 1988-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3556135
• 关键词: 6 thioguanine; 6 thiopurine; Hodgkin's disease; adult human (21+); asparaginase; cancer rehabilitation /care; carmustine; child (0-11); combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cytosine arabinoside; daunorubicin; enzyme therapy; fluorouracil; human subject; human therapy evaluation; lymphocytic leukemia; lymphoma; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neuroblastoma; pediatric neoplasm /cancer; prednisone; reticuloendotheliosis

Personnel listed in this grant application constitute a group of clinical investigators in the field of Surgical, Radiation or Medical Oncology who collectively are recognized and accepted as a member institution of the Cancer and Leukemia Group B (CALGB). Mass. General Hospital investigators in Boston, Ma. share the goals of the CALGB to collaborate in the prosecution of clinical investigations in adult neoplasms including acute and chronic leukemias, lymphomas, respiratory cancer, breast cancer and a limited number of other solid tumors. The aim of the group is to accrue as many patients as possible to the approved CALGB protocols and to prosecute these clinical studies with distinction. The protocols written by members of the CALGB incorporate experimental design appropriate to the phase of a particular investigation. In general, the group engages in Phase II protocols attempting to evaluate the role of new agents in selected diseases or Phase III protocols attempting to evaluate the relative effectiveness of 2 or more treatment strategies. By carrying on such studies, the group hopes to clarify optimal programs as treatment as rapidly as possible and to improve clinical management of patients with neoplastic diseases. The range of group studies may involve multidisciplinary studies incorporating pathologic review, chemotherapy, radiation therapy, immunotherapy and psychiatry or they may be limited to any one of these modalities. Principal investigator, Dr. Robert Carey, will have the responsibility of coordinating research activities of the affiliated Mass. General Hospital Investigators. The MGH Group is a consortium of experienced oncologists, surgeons, pathologists, psychiatrists, and internists concerned with aspects of neoplastic disease and who desire to work together in a non-coersive, voluntary association in order to answer important therapeutic questions in cancer management by participation in clinical studies of CALGB.

本赠款申请中列出的人员构成了一组临床 手术，辐射或医学肿瘤学领域的研究人员 集体被认可并被接受为成员机构 癌症和白血病B（CALGB）。 马萨诸塞州综合医院调查员 在马萨诸塞州波士顿。分享CALB的目标以合作 起诉包括急性在内的成人肿瘤的临床研究 和慢性白血病，淋巴瘤，呼吸癌，乳腺癌和A 其他实体瘤数量有限。 小组的目的是累积 许多患者可以通过批准的Calgb方案并起诉 这些临床研究有所不同。 成员编写的协议 Calgb的结合了适合A阶段的实验设计 特定的调查。 通常，该小组参与试图评估的II期协议 新药物在选定疾病或第三阶段方案中的作用 试图评估2个或更多处理的相对有效性 策略。 通过进行此类研究，该小组希望澄清 尽可能快速治疗的最佳计划并改善 肿瘤疾病患者的临床管理。 范围 小组研究可能涉及纳入的多学科研究 病理综述，化学疗法，放射疗法，免疫疗法和 精神病学，否则它们可能仅限于这些方式中的任何一种。 首席调查员罗伯特·凯里（Robert Carey）博士将负责 协调群落综合医院的研究活动 调查人员。 MGH集团是经验丰富的肿瘤学家的联盟， 外科医生，病理学家，精神科医生和内科医生 肿瘤疾病的各个方面，谁渴望在 为了回答重要 通过参与癌症管理中的治疗问题 Calgb的研究。